Insider Selling: LifeStance Health Group (NASDAQ:LFST) CTO Sells 44,394 Shares

LifeStance Health Group, Inc. (NASDAQ:LFST) CTO Vukasin Paunovich sold 44,394 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $481,674.90. Following the sale, the chief technology officer directly owned 247,446 shares of the company’s stock, valued at approximately $2,684,789.10. The trade was a 15.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

LifeStance Health Group Price Performance

NASDAQ LFST traded up $0.73 during trading hours on Wednesday, reaching $12.23. 6,069,393 shares of the company’s stock were exchanged, compared to its average volume of 3,436,752. The stock has a market cap of $4.74 billion, a PE ratio of 94.08 and a beta of 1.14. LifeStance Health Group, Inc. has a one year low of $4.77 and a one year high of $12.43. The firm has a fifty day moving average of $10.10 and a 200-day moving average of $8.12. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The firm had revenue of $435.35 million during the quarter, compared to analysts’ expectations of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The business’s revenue was up 26.1% on a year-over-year basis. During the same period last year, the firm posted ($0.01) EPS. On average, equities research analysts predict that LifeStance Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

Institutional Trading of LifeStance Health Group

A number of hedge funds have recently modified their holdings of LFST. Quantbot Technologies LP acquired a new position in LifeStance Health Group during the second quarter valued at approximately $111,000. Ieq Capital LLC acquired a new stake in LifeStance Health Group in the second quarter worth $1,935,000. Allworth Financial LP bought a new position in shares of LifeStance Health Group during the second quarter worth $284,000. Virtus Advisers LLC bought a new position in shares of LifeStance Health Group during the second quarter worth $1,232,000. Finally, Vise Technologies Inc. acquired a new position in shares of LifeStance Health Group in the 2nd quarter valued at $174,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LFST has been the topic of several research reports. KeyCorp upped their price target on shares of LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Barclays raised their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday, July 14th. BTIG Research upped their target price on shares of LifeStance Health Group from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Canaccord Genuity Group increased their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings upgraded shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $11.62.

Trending Headlines about LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Analyst upgrades support the rally: BTIG Research raised its price target from $15 to $16 while maintaining a Buy rating. Morgan Stanley also reaffirmed its Buy rating, reinforcing Wall Street confidence in LifeStance’s growth prospects. BTIG Raises LifeStance Price Target Morgan Stanley Reaffirms Buy Rating
• Positive Sentiment: Zacks upgraded LFST to Rank #2 (Buy): The upgrade reflects growing optimism about LifeStance’s earnings prospects and could attract additional near-term buying interest. LifeStance Health Upgraded to Buy
• Positive Sentiment: Shares reached a new 52-week high after the analyst upgrade. The move reflects strong recent momentum, supported by LifeStance’s latest quarterly performance, which included revenue growth of 26.1% year over year and earnings above analyst expectations. LifeStance Sets New 52-Week High
• Neutral Sentiment: LifeStance released survey results highlighting demand for integrated mental-health services during perimenopause and menopause. The findings support the company’s brand and potential service demand but do not represent a direct financial forecast or new contract. LifeStance Menopause Mental Health Survey
• Negative Sentiment: COO Lisa K. Miller sold 47,912 shares worth approximately $520,000, reducing her ownership by 14.55%. While insider sales can be motivated by personal financial planning, the transaction may create a modest sentiment headwind after the stock’s strong advance. SEC Insider Trading Filing

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.